Viridian Therapeutics, Inc./DE Cash and Restricted Cash
Viridian Therapeutics, Inc./DE (VRDN) had Cash and Restricted Cash of $164.99 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $164.99M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $176.35M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $212.38M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $169.65M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $164.99M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $176.35M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $212.38M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $169.65M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $117.32M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $116.22M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $99.59M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $200.32M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $107.67M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $91.64M 10-Q · filed 2025-05-06 |
| 2023-12-31 | $102.83M 10-K · filed 2026-02-26 |
| 2023-09-30 | $111.60M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $87.08M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $88.52M 10-Q · filed 2024-05-08 |
| 2022-12-31 | $155.58M 10-K · filed 2026-02-26 |
| 2022-09-30 | $344.21M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $31.29M 10-Q · filed 2023-08-08 |
| 2022-03-31 | $30.86M 10-Q · filed 2023-05-10 |
| 2021-12-31 | $42.30M 10-K · filed 2025-03-03 |
| 2021-09-30 | $138.88M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $27.70M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $46.49M 10-Q · filed 2022-05-13 |
| 2020-12-31 | $45.90M 10-K · filed 2024-02-27 |
| 2020-09-30 | $30.08M 10-Q · filed 2021-11-05 |
| 2020-06-30 | $30.58M 10-Q · filed 2021-08-12 |
| 2020-03-31 | $36.10M 10-Q · filed 2021-05-07 |
| 2019-12-31 | $24.85M 10-K · filed 2022-03-11 |
| 2019-09-30 | $24.86M 10-Q · filed 2020-11-12 |
| 2019-06-30 | $24.01M 10-Q · filed 2020-08-05 |
| 2019-03-31 | $18.20M 10-Q · filed 2020-05-08 |
| 2018-12-31 | $32.61M 10-K · filed 2021-03-26 |
| 2017-12-31 | $47.44M 10-K · filed 2020-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |